Bill > HB1421

This bill prohibits the sale of gene structure- or function-modifying products in Maryland unless they are labeled with the words "Gene structure- or function-modifying product" and include all potential risks, side effects, adverse effects, and other reasonably possible effects the product may have on users or individuals who may come into contact with the user. The bill defines "gene structure- or function-modifying product" as a product produced using modern biotechnology methods, such as gene editing, RNA interference, and transgenesis, that alters the structure or function of one or more genes in the product. Violations of the bill are subject to criminal penalties, civil penalties, and injunctions. The bill takes effect on October 1, 2024.

Health and Social Services

https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/HB1421?ys=2024RS